The metabolism of tryptophan through kynurenine and serotonin pathways is linked to depression. Here, effects of different drugs with antidepressant properties (vortioxetine, fluoxetine, and ketamine) on various tryptophan metabolites in different brain regions and plasma were examined using tandem mass spectrometry (LC-MS/MS), in Flinders Sensitive Line rats, a genetic rat model of depression, and its controls: Flinders Sensitive Line and Sprague-Dawley rats. Protein levels of kynurenine pathway enzymes were measured in the brains and livers of these rat strains. Furthermore, effects of vortioxetine on tryptophan metabolites were assessed in the cortical regions of lupus mice (MRL/MpJ-Fas Ipr ), a murine model of increased depression-like behavior associated with inflammation. Sustained vortioxetine or fluoxetine (at doses aimed to fully occupy serotonin transporter via food or drinking water for at least 14 days) reduced levels of the excitotoxin quinolinic acid (QUIN) in various brain regions in all rats. Furthermore, chronic vortioxetine reduced levels of QUIN in MRL/MpJ-Fas Ipr mice. Acute i.p. administration of fluoxetine (10 mg/kg) or vortioxetine (10 mg/kg) led to reduced brain 5-hydroxyindoleacetic acid in Sprague-Dawley rats (2, 4, 6, and 8 h) and a similar trend was evident in Flinders Sensitive Line and Flinders Sensitive Line rats after 4 h. In contrast, single or repeated administration of ketamine (15 mg/kg i.p.) did not induce significant changes in metabolite levels. In conclusion, sustained vortioxetine and fluoxetine administration decreased QUIN independent of species, while ketamine was ineffective. These results support the hypothesis that modulating tryptophan metabolism may be part of the mechanism of action for some antidepressants.
Major depressive disorder is (MDD) is a seriously debilitating disease, which the World Health Organization estimates to affect more than 350 million people worldwide (Marcus et al. 2012) . MDD is a heterogeneous disorder with a wide spectrum of symptoms, which challenges the development of efficacious treatments. Current first-line treatment is the selective 5-hydroxytryptamine (serotonin) (5-HT) reuptake inhibitors (SSRIs), which modulate the synaptic levels of this neurotransmitter. However, the time to reach therapeutic efficacy is often delayed by weeks and a significant proportion of patients do not respond adequately to treatment with SSRIs (Posternak and Zimmerman 2005) . In the search for more effective pharmacological treatments, a fast and sustained antidepressant effect has been demonstrated for ketamine (Berman et al. 2000; Zarate et al. 2006) , a glutamatergic N-methyl-D-aspartate receptor (NMDAR) antagonist, suggesting a role for altered glutamatergic signaling in the pathophysiology of MDD. Dysregulation of tryptophan (TRP) metabolism, an essential amino acid that serves as a precursor both to 5-HT and neuroactive metabolites acting on the NMDAR, has been proposed to play a causal role for development of MDD (Bonaccorso et al. 2002; Capuron et al. 2003; Eisenberger et al. 2010; Raison et al. 2010) . Thus, TRP metabolism represents an intriguing interface between the serotonergic and glutamatergic hypotheses of depression, however there is a lack of knowledge about the impact of antidepressants.
As a substrate for the synthesis of both 5-HT and NMDAR ligands in the kynurenine (KYN) pathway, TRP metabolism represent a point of convergence for the serotonergic and glutamatergic systems, which can be regulated by factors related to depression. TRP gives rise to the NMDAR antagonist kynurenic acid (KYNA) (Fig. 1) or, through the kynurenine 3-monooxygenase pathway (KMO pathway), the agonist quinolinic acid (QUIN) downstream from KYN (Schwarcz et al. 2012) . Inflammation and stress can increase the levels of key enzymes converting TRP to KYN, i.e. indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) (Oxenkrug 2010; Ball et al. 2014) and increased conversion of TRP to KYN has been reported in depressed patients (Capuron et al. 2003; Raison et al. 2010) as well as in animal models with experimentally induced depression-like behavior (O'Connor et al. 2009; Laugeray et al. 2010) . Activation of TDO and IDO could infer increased levels of metabolites downstream from KYN, of which several are potential neurotoxins including 3-hydroxykynurenine (3-HKYN) and 3-hydroxyanthranilic acid (3-HANA) (Schwarcz et al. 2012) . QUIN in particular has been under investigation as it has been reported increased in depressed and suicidal patients (Steiner et al. 2011; Erhardt et al. 2013; Bay-Richter et al. 2015) and furthermore, the level of cerebrospinal fluid QUIN correlates with the severity of depression (Raison et al. 2010) . In addition to its NMDAR mediated excitotoxic actions, QUIN may also promote gliosis and contribute to neural toxicity by several other mechanisms (reviewed in Guillemin 2012; LugoHuitr on et al. 2013) .
A recent study showed that chronic treatment with the SSRI, escitalopram decreased QUIN and 3-HKYN blood levels in depressed patients (Halaris et al. 2015) , but it is unknown whether this effect is present in the brain. This would be particularly relevant to investigate as QUIN is not considered to be a metabolite that cross the blood-brain barrier at a considerable rate (Foster et al. 1984; Kitt and Spector 1987; Fukui et al. 1991) . In general, the effects of antidepressants on the KYN branch of TRP metabolism are not fully characterized. One in vivo study showed that chronic administration of the atypical antidepressants, agomelatine, reduced KMO mRNA expression in rat hippocampus (HIP) (Molteni et al. 2013) . However, most studies so far conducted have examined the impact of antidepressant on KYN metabolism in vitro or ex vivo. These studies suggest that SSRIs impact TRP metabolism by limiting the production of KYN metabolites via regulation on TDO or IDO Evans 1981, 1982; Bano and Sherkheli 2003; Kocki et al. 2012; da Silva Dias et al. 2016) or shift the KYN catabolism away from the neurotoxic KMO pathway towards the potential neuroprotective KYNA by regulating relevant enzymes (Kocki et al. 2012) . Moreover, both ketamine and SSRIs are known to impact cells of the immune system and are hereby able to influence the pathway through inflammation-responsive enzymes, which could include most of the KYN pathway enzymes, depending on tissue and cell type (Asp et al. 2011; Zunszain et al. 2012; Leonard 2014; Jones et al. 2015; da Silva Dias et al. 2016; Wang et al. 2015) . Furthermore, SSRIs may affect corticosterone levels in rodents and hereby alter TRP metabolism via TDO (Hesketh et al. 2005; Ara and Bano 2012) . Figure 1 Metabolism of tryptophan (TRP) through kynurenine (KYN) and serotonin (5-HT) pathways and the proposed mechanisms of antidepressants (ADs). Metabolites (capital, black) and enzymes (capital, blue) measured in these studies. Currently proposed mechanisms of antidepressants are presented in green as inhibitory on TDO, IDO and the KMO pathway and stimulatory on kynurenic acid (KYNA) production. Potential neurotoxins are shown in red. 3-HKYN, 3-hydroxykynurenine; 5-HIAA, 5-hydroxyindoleacetic acid; ANA, anthranilic acid; HAAO, 3-hydroxyanthranilate 3, 4-dioxygenase; IDO, indolamine-2,3-dioxygenase; KAT, kynurenine aminotransferase; KMO, kynurenine-3-monoxygenase; KYNU, kynureninase; MAO, monoamine oxidase; NTA, nicotinamide; QPRT, quinolinic acid phosphoribosyltransferase; QUIN, quinolinic acid; TDO, tryptophan 2,3-dioxygenase; TPH, tryptophan hydroxylase.
There is a lack of studies that directly measure the levels of the metabolites with antidepressant treatment in both brain and the periphery. The liver plays a vital role in amino acid metabolism as it is the first organ to metabolize absorbed dietary TRP. It hereby controls the release of tryptophan metabolites to the systemic circulation. Furthermore, expression of several KYN pathway enzymes are many fold higher in the liver than in the brain according to the human proteome map (accessed February 2017). Thus, the liver provides precursors and side-intermediates for TRP metabolism to other organs, including brain, and may hereby represent one of the key regulators of KYN metabolite levels in the bloodstream.
Therefore, this study systematically investigated the effects of different drugs with antidepressant properties on TRP metabolites, including 5-HT and KYN pathway metabolites, in three different rat strains and a mouse model of neuroinflammation. The Flinders Sensitive Line (FSL) rat is a genetic rat model displaying consistent depression-like behavior in the forced swim test and furthermore, shows altered TRP metabolism including increased brain levels of the QUIN precursor, 3-HKYN and decreased anthranilic acid (ANA), compared to its selectively bred control, the Flinders Resistant Line (FRL) rat (Eskelund et al. 2016) . The FSL and FRL rats were originally bred from Sprague-Dawley (SD) rats and exhibit a high degree of predictive validity, since all clinically used classes of antidepressants, including ketamine, show antidepressant activity measured in the forced swim test (Overstreet and Wegener 2013; Liebenberg et al. 2014; du Jardin et al. 2016a; Ardalan et al. 2016) . We additionally utilized the MRL/MpJ-Fas lpr (MRL/lpr) murine model of lupus, which exhibits depression-like behavior and changes in immunological factors associated with increased levels of metabolites in the potential neurotoxic KMO pathway, including 3-HKYN, 3-HANA and QUIN (Gao et al. 2009; Li et al. 2015) . Thus, FSL rats and lupus mice represent two different genetic animal models, however both have depression-like symptoms possibly related to changes in the 5-HT and KYN pathways of TRP metabolism.
Antidepressants with different mechanisms of action were used, including the multimodal antidepressant vortioxetine, which is a 5-HT transporter (SERT) inhibitor and a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a partial 5-HT 1B receptor agonist and a 5-HT 1A receptor agonist. Furthermore, the prototypic SSRI fluoxetine and NMDA receptor antagonist ketamine were used. Ketamine provides fast onset of antidepressant activity (within hours) in both humans (Berman et al. 2000; Zarate et al. 2006) and rats (Garcia et al. 2008; Koike et al. 2011; Carrier and Kabbaj 2013; Gigliucci et al. 2013; Yang et al. 2013) . Therefore, since the active treatment regimens differ for ketamine and fluoxetine/ vortioxetine, we characterized the changes in TRP metabolite levels after both acute and chronic dosing.
With this experimental setup, we hypothesized that antidepressants would cause a general reduction in levels of metabolites downstream TRP or shift the metabolism from the neurotoxic KMO branch towards KYNA production.
Materials and methods

Animals
All animals were housed in a controlled environment of 20-22°C and 60% humidity under a 12 : 12 hour light : dark schedule (photoperiod 6:00-18:00 hours) with ad libitum access to water and food.
FSL and FRL rats were kept at the Risskov colony (Aarhus, Denmark), whereas SD rats were obtained from Taconic (Ejby, Denmark). All rats were housed two per cage and left to habituate for at least 2 weeks prior to any intervention. All rats were handled daily prior to the experiments for at least 4 days. Furthermore, on the day of euthanasia the rats were acclimatized in a separate room for at least 1 h to reduce stress. To avoid potential confounding effects from the circadian rhythm of TRP metabolism, rats were randomly allocated to the different treatment groups and order of euthanasia. This was done by randomizing a list with id numbers of the rats using an online tool (www.random.org). For example, a list consisting of SD rats was randomized, and the order of appearance on the randomized list determined which treatment animals were given. For instance, the first six rats on the randomized list were allocated to the vehicle treatment. Once all treatments were allocated to individual animals, a list containing all animals was randomized, and the order on this list determined the location of the animal in the vivarium and the order of euthanasia. Therefore, randomizing all animals and treatments additionally ensured that the experimenter was semi-blinded. Furthermore, during sample preparation and analysis on the LC-MS/MS, this randomized order was kept. Our sample sizes were derived from previous studies (Zangen et al. 1997 ) and a power calculation (power, 1-b = 0.8 and a = 0.05). Inclusion criteria were age and gender, whereas no exclusion criteria, except humane endpoints, were defined. No animals reached the humane endpoints: severe weight loss, lack of general activity and lack of self-hygiene All animal procedures were approved by the Danish National Committee for Ethics in Animal Experimentation (permission id: 2012-15-2934-00254) . The results obtained for vehicle-treated FSL, FRL and SD rats from experiments 2 and 3 are described separately elsewhere (A. Eskelund, in preparation 2017 Experiment 1: acute treatment in SD rats 72, male, SD rats (8 weeks) were treated with vortioxetine (10 mg/kg) or ketamine (15 mg/kg) and euthanized by decapitation 2, 4, 6, and 8 h later. Vortioxetine and ketamine were dissolved in sterile water and administered at a volume of 2 mL/kg i.p. This dose of ketamine provides a robust and sustained antidepressant activity in the forced swim test in FSL rats (Liebenberg et al. 2014; du Jardin et al. 2016a; Ardalan et al. 2016 ) and other rat strains (Garcia et al. 2008; M€ uller et al. 2013; Yang et al. 2013) . The vortioxetine dose corresponded to a therapeutically relevant SERT occupancy > 80% (Scheffel et al. 1994; Meyer et al. 2004; Pehrson et al. 2015) . All injections were carried out between 6 and 7 a.m. Brains were quickly removed and the right hemisphere including the cerebellum was isolated using a razor blade and snap-frozen in À30°C isopentane. Tissues and plasma were stored at À80°C until analysis.
Experiment 2: acute treatment in FSL and FRL rats 10-12 weeks old, male FSL (n = 22) and FRL (n = 18) rats were treated with fluoxetine (10 mg/kg), vortioxetine (10 mg/kg) or ketamine (15 mg/kg). All antidepressants were dissolved in sterile water and administered i.p. at a volume of 1 mL/kg between 7 and 9 a.m. and animals killed after 4 h (11 a.m. to 1 p.m.). Brains were quickly removed and dissected into the following areas as previously defined (Glowinski and Iversen 1966) : hypothalamus, frontal cortex [corresponding to the coronal area anterior to Bregma 3.70 mm (Paxinos and Watson 1998) ], HIP, striatum, midbrain (MB), cerebellum (CB), and rest of brain (RB). Tissues were frozen in powdered dry ice and trunk blood collected in K 3 -EDTA coated tubes standing in ice and centrifuged (2650 g, 10 min, 4°C) to obtain plasma. Tissues and plasma were stored at À80°C until analyses.
Experiment 3: sustained treatment to FSL, FRL, and SD rats 8-10 weeks old, male FSL (n = 32), FRL (n = 16) and SD (n = 32) rats were allocated to four groups [vortioxetine, fluoxetine, ketamine or vehicle] and treated for a total of 14 days as described below. Administration and dose of fluoxetine and vortioxetine were chosen to represent clinically relevant treatment regimens [> 80% SERT occupancy (Li et al. 2013) ], i.e. via vortioxetine-infused food (600 mg/kg LabDiet 5001 chow, Research Diets, Inc., New Brunswick, NJ, USA) or fluoxetine containing drinking water (160 mg/L) as previously described (Dulawa et al. 2004; Wallace et al. 2014) . Fluoxetine in drinking water has earlier been shown to provide antidepressant-like relief in the forced swim test (Jiao et al. 2011; Bath et al. 2012; Li et al. 2013) . For ketamine [15 mg/kg/mL intra peritoneal (i.p.)] we chose to use an intermittent dose regimen with injection every 3rd day, which demonstrate effective antidepressant effects . Therefore, all other experimental groups received a saline injection 1 mL/kg i.p every 3rd day. Standard rat chow and tapwater served as vehicle for the per os (p.o.) treatments. Water and food intake were monitored every 3rd day (when rats were weighed and injected) and, the average daily dietary dose of vortioxetine was~48 mg/kg and~13.3 mg/kg for fluoxetine ( Figure S1 in Appendix). Animals were killed the day after the last injection, where brains regions and plasma were extracted as described in experiment 2.
This experiment was repeated and additionally, whole livers were excised, frozen in dry ice snow and kept at À80°C until further analyses.
Experiment 4: chronic dietary vortioxetine administration to MRL/lpr mice Female MRL/lpr mice (n = 20) received vortioxetine-infused food (600 mg/kg chow) or control food for 10 weeks and their congenic strain MRL (n = 10) was included as control. Animals were killed by carbon dioxide inhalation followed by decapitation. Frontal cortex was dissected, snap-frozen and stored at À80°C until further analysis. Ana, CA, USA) for 5 min at 1200 oscillations/min. Larger tissues were homogenized using Omni-Prep Multi-Sample Homogenizer with disposable blades (ThermoFisher Scientific, Waltham, MA, USA) for 5 min. Diluted samples were then filtrated through 3 kDa Amicon Ultra filter (EMD Millipore, Billerica, MA, USA) by centrifugation (13 500 g, 60 min, 4°C). Resultant filtrates were hereafter directly injected (20 lL) into a Waters Acquity HPLC system (Waters Corporation, Milford, MA, USA) equipped with an YMC TM ODS-AQ TM 2 9 100 mm, 3 lm particle column using a gradient elution (A: 0.5% formic acid in aqueous solution/B: 1% formic acid in acetonitrile). Separated metabolites were detected by a Waters Quattro Premier XE triple quadrupole mass spectrometer, Waters Corporation, Milford, MA, USA), operating in the MS/MS mode as previously described (Mazarei et al. 2013) . Average concentrations were based on triplicate measures, except for hypothalamus, where only 1-2 injections were obtained due to low volume of sample material. All samples and reagents were of HPLC grade, corresponding to 98-99% purity.
LC-MS/MS
5-HTP is only reported for brain [not reliably detected in plasma with used method (%CV > 15)]. Furthermore, brain tissue levels of xanthurenic aid and 3-HANA are below detection limit in rats. Brain PA had an interfering peak in both species and were therefore excluded from analyses. As a result of the large amounts of samples each brain region was run separately on the system.
Western blot
Frozen livers were crushed to powder inside a homemade metal pestle by mechanical force using a large hammer. Great care was taken to avoid any thawing by keeping all materials on dry ice constantly. Furthermore, all instruments were cleaned thoroughly with detergent and Ambion RNAse AWAY TM (ThermoFisher Scientific), re-immersed in dry ice and allowed to cool between each sample. Frozen liver powder was diluted by a factor 911 in Bio-Plex â Cell Lysis Kit (Bio-Rad Laboratories, Copenhagen, Denmark) containing protease inhibitors and homogenized together with 2 9 4 mm stainless steel beads using a Mixer Mill MM 400 homogenizer (Retsch GmbH, Germany). Samples were frozen overnight at À80°C and after thawing, ultrasonicated (40% power, 4 s, sample kept in ice) using sonopuls HD 2200 (Bandelin, Haan, Germany). Supernatant was obtained by centrifugation (4 500 g, 4 min, 4°C) and total protein concentration was determined by Pierce TM bicinchoninic acid Protein Determination Assay kit (ThermoFischer Scientific) using bovine serum albumin to generate a standard curve. Protein samples (diluted to 3 lg/lL) were denatured by heating (15 min, 50°C) in sodium dodecyl sulfate sample buffer (2 : 1) (125 mM Tris-HCl, pH 6.8/20% glycerol/4% sodium dodecyl sulfate/0.02% bromophenol blue) using dithiothreitol (125 mM) as reducing agent. A total of 20 lg protein per lane was separated using a 26-well, TGX precast 10% polyacrylamide gel in the Criterion TM Cell system (Bio-Rad Laboratories) according to manufacturer's instructions. Proteins were transferred to a 0.2 lm midi nitrocellulose membrane using the Trans-Blot â Turbo TM Transfer System (Bio-Rad Laboratories). After blocking, blots were incubated with primary antibodies over night at 4°C, and subsequently allowed to react with fluorochrome-conjugated secondary antibodies (IRDye â (LI-COR Biosciences UK Ltd, Cambridge, UK)) in the dark for 1 h at room temperature (~21 C). Blots were washed extensively between each step as previously described (Mathews et al. 2009 ). The infrared signals were detected in the Odyssey CLx Western Blot Detection System (LI-COR Biosciences UK Ltd, Cambridge, UK). Using Image Studio software (LI-COR Biosciences), median intensities of individual bands were corrected to the background and normalized to loading controls a-tubulin, b-tubulin or b-actin. Choice of loading control was dependent on which species the antibody was raised in and availability, however, it was tested that all reference proteins displayed homogenous levels across experimental groups. Results obtained from rat plasma or brain hemispheres were analyzed by full factorial, two-way multivariate analysis of variance (MANOVA) using treatment 9 strain or treatment 9 time as categorical dependent variables. Multivariate interactions were followed up, by examining whether the interactions were present for each dependent variable, separately (multiple univariate analyses). In the experiments with several brain regions (experiment 2 and 3), oneway mixed ANOVAs were performed using brain region as the repeated within-factor and Greenhouse-Geisser to compensate for departures from sphericity (e < 0.75). Significant three-way interactions were followed up by multiple two-way ANOVAs within each brain region. With significant two-way interactions with treatment (between or within) in the (M)ANOVAs, simple main effects were reported instead of main effects. Statistical differences between metabolites measured in MRL (vehicle), MRL/lpr (vehicle) and MRL/lpr (vortioxetine) were analyzed by one-way MANOVA. Differences in enzyme proteins levels were analyzed by either unpaired ttest (two groups) or one-way ANOVA (three groups).
Assumptions of MANOVAs, ANOVAs and t-tests were checked by analysis of the standardized residuals and outliers were defined as residuals exceeding AE 3. To reduce the probability of finding false significant effects simply because of multiple comparisons (Type 1-error), a false discovery rate of q* ≤ 0.05 was applied according to the principles described by Bejamini and Hochberg (Benjamini and Hochberg 1995) . Final pairwise comparisons of fluoxetine, vortioxetine or ketamine treatment to vehicle were adjusted using Bonferroni correction and the level of significance after corrections, defined as p < 0.05.
Data are shown as mean AE 95% confidence intervals (CI) (in figures), or mean ratio (fraction compared to vehicle), with 95% CI (in text), unless otherwise stated. All results from transformed data have been reverse-transformed.
Results
Effects of acute drug administrations
Time course of vortioxetine-and ketamine-induced effects on TRP metabolism were first examined in the right hemisphere and plasma of the commercially available SD rat (at 2, 4, 6 and 8 h).
In the SD rat brain the effects of treatment on the combined metabolites were dependent on time, specifically vortioxetine increased brain KYN levels 6 h post dosing by 52% compared to vehicle (0.52 (95% CI, 0.1-1.1), p = 0.007, see Table S1 in Appendix for absolute values). Contrary, 5-HIAA levels were reduced by vortioxetine in brain regardless of time points (0.26 (95% CI, 0.06-0.51), p = 0.005). In plasma (Table S2 in Appendix), TRP levels were reduced in plasma by vortioxetine (À0.17 (95% CI, À0.25 to À0.07), p = 4.9 9 10 À7 ), independent of time point. Furthermore, for ketamine, which has antidepressant properties within hours, we noted a trend for increased ANA in brain 4 h post dosing (Table S1 in Appendix) . We then proceeded to investigate effects of single fluoxetine, vortioxetine, and ketamine administrations on TRP metabolite levels in the FSL rat model compared to its control, the FRL rat. We chose to explore changes in metabolite levels after 4 h, as there was a trend for increased ANA in the SD rat and this potential anti-oxidant is low in FSL rats. For this purpose, we dissected the brain into regions as distinct focal metabolite changes could have been masked when examining the brain in its entirety.
Effects were found mainly in FSL plasma F treat 9 strain (3,29) = 3.3, p = 0.034, g 2 p = 0.26). Thus, ANA levels were increased compared to vehicle, regardless of treatmentfluoxetine (0.66 (95% CI, 0.17-1.34), p = 0.0016), vortioxetine (0.51 (95% CI, 0.11-1.05), p = 0.0044) and ketamine (0.55 (95% CI, 0.14-1.11), p = 0.0023) (Absolute levels shown in Figure S2 and Figure S3 in Appendix). Similarly, plasma PA levels were increased in FSL rats with treatment [(F treat 9 strain (3,29) = 3.6, p = 0.025, g ). NTA could not be determined in striatum, as a result of a technical error in the mass spectrometry file. In brain, a numeric reduction in brain 5-HIAA by vortioxetine did not reach statistical significance after adjusting for multiple comparisons.
Effects of sustained drug treatments
As SSRIs require prolonged administration for the therapeutic effect to occur, we conducted a study administering clinically relevant doses of fluoxetine and vortioxetine for 2 weeks to all three rat strains within the same study. We additionally included chronic ketamine treatment using an intermittent dosing regimen. The SD rat was included as an auxiliary control as it is the founding strain for the FSL and FRL rat model. Consistent with the earlier experiment, TRP metabolites were examined in seven brain regions and plasma.
Metabolite levels in rats There were trends for reduced levels of brain KYN, KYNA and 3-HKYN in the controls, SD and FRL rats with fluoxetine and vortioxetine, although not statistically significant ( Figure S4 in Appendix). However, fluoxetine or vortioxetine significantly reduced the level of QUIN in all brain regions, independent of rat strain (Fig. 2a) Chronic treatment furthermore, led to brain region-specific reductions in the serotonergic arm of TRP metabolism. 5-HTP was significantly reduced in RB and CB (Fig. 2b) (Fig. 2e) .
Kynurenine pathway enzymes in rat liver and hippocampus One possible mechanism for the observed changes in QUIN in both plasma and brain is altered expression levels of enzymes related to the kynurenine pathway in the periphery. Tissue-dependent expression of the various enzymes in the kynurenine pathway have been reported, and the liver may contribute substantially to the metabolite levels in plasma.
Using a western blotting approach, total protein levels of IDO, KMO, KYNU, HAAO, QPRT, KATII+IV were measured in the liver and hippocampal homogenates of rats (Fig. 3) . HAAO, QPRT, KYNU and KAT2 were only detectable in liver and KMO antibody did not recognize a protein at the expected molecular weight in brain. Therefore, analyses of these proteins are only included for liver. Among all the detectable targets, we did not find significant changes of enzymes in both FSL and SD rats that could explain reduced QUIN with treatment.
Metabolite levels in MRL and MRL/lpr mice frontal cortex Up to this point, we have only investigated the effects of antidepressants on the TRP metabolism in male rats, however, it is known that the diagnosis of MDD is more prevalent in women than in men. Furthermore, for external validity we wanted to explore whether our findings would be present in other species with depression-like behavior. Therefore, to extend our findings we explored the effects of vortioxetine in female MRL/lpr mice, which display complex immunological changes and increased kynurenine pathway metabolites downstream tryptophan. Finally, as chronic treatment in humans usually requires more than 2 weeks' treatment, we extended the treatment period to 10 weeks.
There was a significant overall effect of long-term vortioxetine treatment on the TRP metabolites in frontal cortex (overall MANOVA: F treat (22,18) = 5.5, p = 2.6 9 10 À4 , g 2 p = 0.87 and Wilks' Λ = 0.02). Similar to the findings in rats, chronic vortioxetine significantly reduced levels of QUIN (Table 1 ) (À0.29 (95% CI, À0.43 to À0.13), p = 0.0028) but there was no significant effect of vortioxetine treatment in the 5-HT branch of TRP metabolism. There were additionally trends for reduced 5-HTP, 5-HIAA and ANA, but these did not remain significant after correction for multiple comparisons. (e) *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Figure 2 Chronic administration of fluoxetine or vortioxetine decreased quin levels and altered serotonergic metabolites. QUIN levels (a) are significantly reduced with chronic (14 days p.o.) vortioxetine (VORT, dark gray) or fluoxetine (FLX, light gray) in all examined brain regions and plasma compared to vehicle (VEH, white). Brain 5-HTP (b) and 5-HT (c) levels showed region-dependent reductions with FLX or VORT, whereas plasma 5-HT was reduced with both FLX and VORT. 5-HIAA (d) was decreased independent of region in all rat strains, but only by VORT in plasma. There were no statistically significant effects of chronic intermittent ketamine (KET, black) (14 days, every 3rd day, i.p.). Furthermore, KYN/TRP (K/T) ratio was unaltered (e). Bonferroni corrected p-values are denoted as ***p < 0.001, **p < 0.01, *p < 0.05 and n = 4-8/group. FCTX, frontal cortex; HIP, hippocampus; STR, striatum; MB, midbrain; HYP, hypothalamus; RB, rest of brain; CB, cerebellum.
animal models with depression-like phenotype. Our main findings were statistically significant decreased QUIN levels, in plasma and brain after chronic vortioxetine or fluoxetine treatment, but not acute treatment (< 8 h). Furthermore, a reduction in brain 5-HIAA was evident with vortioxetine treatment from 2 h post administration. Contrary, we found no robust effect of ketamine on the metabolite levels measured.
The decreases in QUIN with antidepressants is particular interesting as QUIN is a potential neurotoxin (Guillemin 2012) , which is increased in depression and its level correlates positively with the severity of depressive symptoms (Raison et al. 2010; Steiner et al. 2011) . With sustained treatment, QUIN was consistently reduced in all rat brain regions by up to 33% by fluoxetine 29% by vehicle (VEH, white) in bar charts. As there were no changes in the metabolite levels with ketamine, these samples were not run on western blot. Bar charts represent the signal intensities achieved after normalization to the loading control and insert below each bar chart demonstrates representative immunoreactive bands. n = 8-10/group. Abbreviations are explained in Fig. 1 .
vortioxetine, furthermore in mouse frontal cortex by 38%. In rat plasma QUIN was reduced 31% by fluoxetine and 50% by vortioxetine. This data corroborate a study showing a 50% decrease in QUIN levels in plasma from depressed individuals undergoing chronic escitalopram treatment (Halaris et al. 2015) and is the first study to demonstrate that a significant decrease occurs concurrently in rat plasma and brain after treatment with other drugs inhibiting SERT. In an attempt to clarify the mechanisms by which fluoxetine and vortioxetine decrease QUIN, we investigated levels of KYN pathway enzymes in rat liver and HIP by western blotting. However, we did not find consistent changes across rat strains with treatment. The liver was investigated because it is the primary organ involved in amino acid and xenobiotic metabolism, has high expression levels of enzymes of the kynurenine pathway and is important for maintaining both brain and plasma QUIN levels (Basile et al. 1995a) . However, enzyme monomer levels may not necessarily reflect enzyme activity accurately as reductions in cofactors or consumption of metabolites into other interweaving pathways could lead to changes in metabolite levels. Thus, future studies of antidepressant effects may focus directly on measuring activity of enzymes with relevance to QUIN levels. Overall, our measures of KYN pathway metabolites in three different rat strains and a mouse model of depression only lend partial support for the hypothesis that the turnover of TRP to KYN is inhibited by antidepressants. With chronic fluoxetine or vortioxetine treatment, brain levels of KYN, 3-HKYN and partly KYNA, tended to be decreased in FRL and SD rats. This was not observed in brains from FSL rats or MRL/lpr mice and furthermore, similar trends were absent in plasma from all rats. The KYN pathway is assumed to be segregated in brain tissue (Schwarcz and Stone 2017) , therefore it is possible that measuring whole tissue homogenate masks effects previously reported on brain KAT, KMO and IDO (Kocki et al. 2012; da Silva Dias et al. 2016) . Furthermore, potential metabolic changes caused by antidepressant-induced effects on liver TDO Evans 1981, 1982; Bano and Sherkheli 2003) may not be evident in the plasmatic metabolic makeup, and unfortunately, we were not able to detect TDO using western blotting.
By examining both metabolism in the periphery and brain we additionally hoped to establish whether reduced QUIN was a globally mediated effect or initiated locally in a tissue with high expression of the relevant enzymes and from thereon propagated to the brain. Fluoxetine and vortioxetine induce a larger percentage decrease in QUIN in plasma compared to brain, although both drugs cross the blood-brain barrier, and are not substrates for p-glycoproteins to a large extent (Doran et al. 2005; Bundgaard et al. 2016) . As previously stated, QUIN does not cross the blood-brain barrier at a considerable rate when measured in acute studies (Foster et al. 1984; Kitt and Spector 1987; Fukui et al. 1991) , although we (Eskelund et al. 2016) and others (Heyes and Morrison 1997) have shown that QUIN levels strongly correlate between brain and plasma. Interestingly, Heyes et al. (1997) showed in longer lasting studies that bloodderived QUIN contributes to cerebral pools of up to~60%. Thus, it may be not be unreasonable to speculate that a peripherally-induced change in QUIN eventually would manifest cerebrally. As a result of the inability to characterize the brain enzymes of the pathway with our study design this question remains unanswered.
In the 5-HT pathway, a strong reduction in plasma 5-HT and partly reduced 5-HIAA with chronic fluoxetine or vortioxetine is consistent with previous studies and most likely reflects SERT inhibition on the thrombocytes leading to reduced 5-HT in platelets (Alvarez et al. 1999; BismuthEvenzal et al. 2012; Zhu et al. 2013) . In brain, more robust reduction of 5-HIAA than that of 5-HT have been reported in previous studies with SSRIs (Caccia et al. 1992; Thompson et al. 2004; Dygalo et al. 2006) . In fact, Caccia et al., demonstrated that the regional reduction in 5-HT is dependent not only on the route of administration, but also on the treatment duration. The reduction in 5-HIAA may be a direct consequence of serotonin transporter inhibition, which result in a reduction in 5-HT levels in the presynaptic neurons, where it breaks down to 5-HIAA. The reduction in 5-HT could be caused by inhibition of 5-HT synthesis by chronic SSRI treatment (Dygalo et al. 2006; Honig et al. 2009 ). However, as 5-HT is an intermediate for an array of other products (for example, melatonin), it may be regulated in a complex manner with many compensatory mechanisms and the excistence of separate 5-HT pools has been described previously (Shields and Eccleston 1973; Curzon et al. 1978; Kleven et al. 1983) . The region-specific brain changes observed in the present study and previous studies may result from a combination of difference in tissue distribution of the systemically delivered drugs, as well as the regional differences in the synthesis and/or metabolic machinery. Therefore, these differences in regulatory mechanisms may results in distinct region-specific changes in 5-HT and 5-HIAA.
Acute administration of antidepressants was applied mainly to evaluate the early antidepressant effect exerted specifically by ketamine in FSL rats compared to fluoxetine and vortioxetine (Overstreet and Wegener 2013) . However, we did not find robust changes induced by ketamine, except a trend or significantly increased ANA and PA in the FSL rats, not the FRL rat, which is interesting since the FSL rat have lower levels of these potential antioxidants (Platten et al. 2005; Darlington et al. 2010; Sasaki et al. 2012; Prodinger et al. 2015; Eskelund et al. 2016) . Sporadic changes in the TRP metabolites were evident with fluoxetine or vortioxetine in the two acute studies, however, these changes are most likely not related to antidepressant effects and could reflect digestive, or adsorptive changes in the gut where a large metabolism of 5-HT occurs. Thus, to evaluate acute effects, further studies are needed, employing different routes of administration to clarify the impact of these antidepressants on TRP metabolites versus metabolism in general.
Previous studies have shown that systemic ketamine administration elicits a rapid and transient increase in extracellular 5-HT levels in medial prefrontal cortex and dorsal raphe nuclei, which occurs within 10 min and decreases to baseline within 3 h (Amarg os- Bosch et al. 2006; L opez-Gil et al. 2012; Nishitani et al. 2014) . This discrepency from our study may result from the difference in neurotransmitter concentrations in extracellular versus tissue homogenates. For example, other studies also reported unaltered 5-HT and 5-HT turnover (5-HT/5-HIAA) by ketamine in brain homogenates 1 h after ketamine administration (Gigliucci et al. 2013; du Jardin et al. 2016a) . Given the antidepressant-like effects of ketamine is 5-HT dependent in rats (Gigliucci et al. 2013; du Jardin et al. 2016a) , it is interesting to exclude the possibility of ketamine directly regulating serotonin metabolism with the dose used. Other possible mechanisms of the serotonergic interplay with the antidepressant action of ketamine has recently been discussed elsewhere (du Jardin et al. 2016b) .
In our study, ketamine did not show any robust changes in TRP metabolism following acute or chronic administration, although long-lasting antidepressant-like activity has been reported in rodents for of up to eight 8 days after single administration (Ma et al. 2013; Yang et al. 2015) , including the FSL rat (Liebenberg et al. 2014; du Jardin et al. 2016a; Ardalan et al. 2016) . This is consistent with a recent human study that does not suggest robust changes in TRP or KYN with ketamine (Rotroff et al. 2016) .
Conclusively, we found a reduction in QUIN of the KMO pathway in brain with fluoxetine or vortioxetine, independent of both rat strain, rodent species and sex. That the effects were present in both animals with depression-like phenotype, as well as control rats, suggest that this effect is indistinct from antidepressant-like effect, which is not observed in FRL rats (Overstreet and Wegener 2013) . Instead, the beneficial effects of these antidepressants may relate to a phenotype with increased vulnerability to NMDAR modulation or reactive oxygen species. As such, dysfunctional glutamatergic signaling and altered NMDAR expression has been widely documented in depression (Karolewicz et al. 2005; Feyissa et al. 2009; Sanacora et al. 2012) . Similarly, both animal models display NMDAR-specific disturbances compared to their control (G omez-Gal an et al. 2012; Marcinko et al. 2012; Treccani et al. 2016) . Considering that thẽ 30% reduction in whole tissue QUIN levels may infer greater changes at the synaptic levels where local amounts of QUIN are released, the composition and levels of NMDARs could be detrimental for the beneficial effect. Thus, a shift in the balance of QUIN/KYNA may prove vital for antidepressant relief in the susceptible subject, whereas healthy controls are unaffected by such a change. Similarly, the capacity for maintaining a normal redox balance may be impaired in depressed and animal models with depression-like phenotype. Therefore, further studies examining the underlying biologic differences in depressed subjects will additionally contribute to a better understanding of which treatments benefit a given patient population.
A limitation of our study is that we only examined effects of antidepressants and ketamine on TRP metabolites along the KYN and 5-HT pathways. Other tryptophan metabolites and pathways, such as the those modulated by gut microflora that interleaves 5-HT and KYN pathways are yet to be studied (Zheng et al. 2010; O'Mahony et al. 2015; Kennedy et al. 2016) . Furthermore, we did not food-deprive animals prior to euthanasia, as we wanted to see the natural metabolite levels. However, animals were killed during the light hours, when they predominantly sleep and therefore, we believe this has inferred negligible experimental variation in our metabolite measures. We conducted our analysis as multiple top-down (M)ANOVAs and applied BenjaminiHochbergs false discovery rate to constrain the possibility of committing a type-I error and producing false significant results. However, given the sample sizes in explorative preclinical research are low, our analyses may not detect smaller effect sizes and therefore, have increased our chances of committing type-II errors. Furthermore, we found that KYN and KYNA often present a few extreme outliers, which are excluded in our parametric analyses. Therefore, we additionally conducted several non-parametric, KruskalWallis tests for effects of fluoxetine, vortioxetine and ketamine on KYN and KYNA, however we still found no changes on these metabolites. Furthermore, we did not examine the effect of vortioxetine in other brain regions of the mice, therefore our brain-region independent reduction in QUIN in rats should not be extrapolated to mice without further studies.
